- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | Theravance, after clinical setbacks, agrees to $929M buyout | ||
| 13:46 | 10 clinical trials to watch in the second half of 2026 | ||
| Fr | FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services | ||
| Fr | At BIO, tension over China biotech deal regulation looms | ||
| Fr | Alkermes' incoming CEO has a plan to outplay Lilly and Takeda | ||
| Fr | On second try, Acadia drug gets nod from European regulators | ||
| Do | Remix Therapeutics to go public in reverse merger with once high-flying Passage Bio | ||
| Do | Antares gets $105M from Novartis for new cancer drugs | ||
| Mi | Investors pour $115M into RQ Bio in search of a preventive flu drug | ||
| Mi | To Wall Street, psychedelics biotechs are more teammates than rivals | ||
| Mi | Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor | ||
| Mi | Ollin refuels with $330M to back pivotal tests of Vabysmo challenger | ||
| Di | Pfizer drug acquired in Seagen deal disappoints in lung cancer study | ||
| Di | How Kardigan spun deal leftovers into a $400M IPO | ||
| Di | HHS, responding to China's rise, moves to fast-track early drug research | ||
| Di | 'The window's open': At BIO, investors take stock of a growing class of biotech IPOs | ||
| Di | Hospitals irate after Eli Lilly follows through on 340B ultimatum | ||
| 22.06. | Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection | ||
| 22.06. | Sanofi swaps R&D leaders; Merck's Prometheus deal pays dividends | ||
| 22.06. | AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs | ||
| 22.06. | Bionyra brings in $165M for next-generation immune drugs | ||
| 22.06. | From episodes to a lifetime: How AI can enable women's health brands to build a partnership that lasts | ||
| 22.06. | The first 14 days: How specialty programs set patients up for success | ||
| 18.06. | Moderna flu vaccine wins unanimous support from FDA panel | ||
| 18.06. | cAMPfield lands $180M to build gut disease drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.